RxDoctor Payments Data

Kumar Sanam

Cardiovascular Disease · Fresno, CANPI 1295049575

Payments from drug & device makers

$133,942in general payments, 2019–2025

Across 310 payments — averaging $432.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$46K
  • Novartis$33K
  • Medtronic$22K
  • Shockwave Medical, Inc$14K
  • Boehringer Ingelheim$7K
  • Penumbra, Inc.$2K
  • plus $10K from 33 others

What the payments were for

  • Consulting fees$6,60012%
  • Speaking & faculty fees$8,93816%
  • Grants$14,80027%
  • Travel & lodging$13,61925%
  • Food & beverage$10,45419%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$133,942 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$335,836
Medicare patients
1,499
Services billed
3,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan100$107,723
EliquisApixaban91$104,560
JardianceEmpagliflozin34$34,726
Repatha SureclickEvolocumab15$12,485
BrilintaTicagrelor13$8,346
Metoprolol Succinate281$3,796
ClopidogrelClopidogrel Bisulfate159$1,743
Ranolazine ErRanolazine12$1,391
Atorvastatin Calcium110$1,092
Bumetanide15$961
Furosemide171$756
Rosuvastatin Calcium50$626
Potassium Chloride40$605
Spironolactone74$579
Losartan Potassium47$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$33,448$107,723100 claims
PfizerEliquis$85$104,56091 claims
Boehringer IngelheimJardiance$6,733$34,72634 claims
AstraZenecaBrilinta$1,872$8,34613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →